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Abstract 
We recently reported that human liver and primary cultures of hepatocytes express calcitonin. We therefore studied the expression of calcitonin 
gene related peptide (CGRP), the alternative splicing product of the calcitonin gene, in hepatocytes and liver. We used polymerase chain reaction 
amplification with specific primers to detect the presence of CGRP I and II messengers and a specific radioimmunoassay to measure the peptide. 
We report here that CGRP is synthesized by primary cultures of hepatocytes and in liver. As liver also possesses pecific receptors for CGRP in 
non-parenchymal cells, a paracrine system could be involved in liver metabolism. 
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1. Introduction 
We have recently reported the presence of calcitonin 
(CT) in both primary cultures of hepatocytes and in 
normal liver tissue [l] and suggested that the hormone 
could be involved in an autocrine/paracrine regulation of 
liver metabolism as the hormone stimulates glycogenoly- 
sis, gluconeogenesis [2], fatty acid synthesis and ATP 
synthesis and lipid metabolism [3].These actions of CT 
on liver metabolism are mediated through cellular 
calcium [4,5] and involve Gs proteins [6]. However the 
calcitonin gene (CALC I) expresses, by tissue specific 
alternative splicing of a common primary transcript, cal- 
citonin gene related peptide (CGRP I) a neuropeptide [7] 
with neurotropic and neurotrophic activity and a potent 
vasodilator [8]. In man and in rat, a second gene which 
is a pseudogene for calcitonin (CALC II) expresses a 
CGRP isomer, CGRP II [9]. Recent studies have demon- 
strated that high concentrations of immunoreactive 
CGRP are present throughout the gut, suggesting an 
important role for CGRP in gastrointestinal function 
and in liver function, as CGRP released from the gut 
accumulates in the portal blood [lo]. More so, specific 
binding sites for CGRP are present in liver [ 11,121. 
In the present work we have investigated whether a 
similar autocrine/paracrine system involving CGRP 
could exist in the liver. We have measured, using a spe- 
cific radioimmunoassay, CGRP levels in human liver 
and in primary cultures of human hepatocytes and 
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searched for its messenger using the polymerase chain 
reaction (PCR) and primers specific for CGRP I, CGRP 
II. We report here that CGRP I is the main form of 
CGRP expressed in both liver and in primary cultures of 
hepatocytes. 
2. Materials and methods 
2.1. Tissue 
Normal tissue obtained from liver resected before hepatic transplan- 
tation was immediately frozen in liquid nitrogen and stored at -80°C 
until required for extraction. 
2.2. Cell isolation and culture 
Normal liver samples were obtained from patients undergoing partial 
hepatectomy. All procedures were performed in compliance with 
French laws and regulations and were approved by the National Ethics 
Committee. Hepatocytes were isolated by the two-step collagenase per- 
fusion method. Subsequently, cells were seeded at a density of IO7 
hepatocytesl80 cm’ flask in 10 ml of a mixture containing 75% mini- 
mum essential medium and 25% medium 99 supplemented with 10 
mg/ml bovine insulin, 0.2% BSA and 10% fetal calf serum. The medium 
was renewed daily and supplemented with 7 x JO-’ M hydrocortisone 
hemisuccinate. 
IT cells, a medullary carcinoma cell line producing high levels of CT 
and CGRP, were cultured in RPMI, 10 mM HEPES, 6 mM glutamine, 
supplemented with 10% foetal calf serum. The medium was changed 
every two days and the cells were harvested at confluence. 
2.3. RNA extraction 
Total RNA was extracted from liver samples and TT cells by a 
guanidine thiocyanate chloride method [ 19. Total RNA was prepared 
from hepatocytes either immediately or after 4 days of culture by 
Chomczynsky’s or Chirgwin’s methods [13,14]. All extracts were imme- 
diately frozen at -80°C or stored at -20°C in 75% ethanol until used. 
2.4. Poiymerase chain reaction 
The sequence of the primers used is reported in Table 1 and their 
position in Fig. 1. Complementary DNA was synthesized from 2 pg of 
total RNA. The reaction mixture in a final volume of 20 ~1, contained 
50 mM KCI, 20 mM Tris-HCI @H 8.4) 2.5 mM MgCI,, nuclease free 
BSA (1 mg/ml), 20 U of RNAsin, 200 U of reverse transcriptase (BRL), 
1 mM of each dNTP and 50 pmol of a 3’-oligo(dT) primer. Annealing 
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was performed during 10 min at 23°C and primer extension during one 
hour at 37°C. The reaction was then diluted to 100 ~1 with the same 
buffer containing 50 pmol of each specific primer and 2.5 units of Taq 
polymerase (Eurobio). Amplification was performed during 25 cycles: 
30 s at 95°C (denaturation), 30 s at 55” C (annealing) and 30 s at 72°C 
(extension). Positive controls with total RNA extracted from TT cells 
and negative ones with RNAs after digestion with RNase A (1 mg/ml) 
one hour at 37°C were performed. 
2.5. Analysis of PCR products 
Amplified products were electrophoresed in 2% agarose gel, visual- 
ized by ethidium bromide and transferred to nylon membrane 
(NEN).The blot was hybridized at 42°C with CGRP-probe (exon 5: 
CGRP coding sequence) radiolabelled with [ti2P]dCTP using a random 
priming method (specific activities > lOa cpm/pg DNA). The mem- 
branes hybridized at 42°C in presence of 50% formamide were washed 
at 55°C. twice in 2 x SSC for 15 min, 2 x SSC containing 0.1% SDS for 
30 min, and 0.1 x SSC for 15 min. Autoradiography was performed at 
-80°C with intensifying screens overnight. 
2.6. Sequencing of PCR products 
After electrophoresis, the specific band was cut from the gel lane 
corresponding to liver tissue. The gel slice was frozen in a Spin-X tube 
(Costar) at -20°C during 20 min. DNA was collected by centrifugation 
at 12,000 x g during 15 min, dissolved and ethanol precipitated then 
resuspended in H,O. 
The amplified products were submitted to PCR with only one inter- 
nal antisense primer, p19 or p39 CGRP I specific primers (Table 1 and 
Fig. 1) labeled with [y-l’P]dCTP and Taq DNA polymerase, to generate 
single stranded template for DNA sequence analysis by the dideoxynu- 
cleotide chain termination method (ds DNA cycle Sequencing System 
BRL): 20 cycles (95°C 30 s, 55°C 30 s, 70°C 60 s) and IO cycles (95°C 
30 s, 70°C 60 s). 
2.7. GRP content 
2.7.1. Tissue extraction. Liver was extracted with 0.1 M acetic acid, 
lyophilised and diluted in RIA buffer (0.1 M phosphate buffer, pH 7.4, 
containing 0.3% human albumin heat denatured, 10 mM EDTA. 10% 
Trasylol (10,000 U/ml, Bayer) and 0.1% sodium azide. 
2.7.2. Primary culture extraction. An aliquot of hepatocyte xtract 
in Chomczvnskv’s olution D (4 M guanidinium thiocvanate. 25 mM 
sodium citrate pH 7, 0.5% sarcosyl, 0.1 M 2-mercaptoethanol) was 
removed prior to phenol extraction and frozen until assayed. 
2.7.3. Radioimmunoassay (RIA). Radiolabelled human CGRP 
(hCGRP) was purchased from Amersham. Assays using antibodies 
specific for hCGRP were performed as previously described [15]. In the 
case of primary cultures, non-specific effects of the extraction 
Chomczynsky’s solution D were controlled by adding equivalent 
amounts of this solution (2.5 ~1) to the standards. 
3. Results Sequence and localisation of the primers used 
3. I. CGRP tissue levels 
Levels of CGRP as estimated by specific RIA were 
90.5 nglg wet weight in liver and 1.43 ng/106 cells in 
cultured hepatocytes. In the RIA, displacement of 
[‘*‘I]hCGRP bound to the specific antibody, by liver or 
cell extracts was identical to that obtained with synthetic 
CGRP. The addition of 2.5 ~1 of Chomczynsky’s solu- 
tion D to the standard curve did not modify the binding 
of the labelled tracer or its displacement (data not 
shown). 
3.2. Analysis of PCR results 
Gel electrophoresis of PCR amplification products ob- 
tained by use of specific primers (~11, ~12) on reverse 
transcripted cDNA revealed the presence in normal 
human liver, primary cultures of human hepatocytes and 
TT cells of a single band stained by ethidium bromide 
(Fig. 2, left). This band had the correct size, 126 bases 
and gave a strong signal after transfer and hybridization 
with a CGRP specific probe, (Fig 2 right). No amplifica- 
tion was observed if the aliquots studied were treated 
with RNase before reverse transcription and amplifica- 
tion. 
CGRP I mRNA is the main CGRP messenger ex- 
pressed in both liver tissue and hepatocytes. Small 
amounts of CGRP II mRNA were detected in liver but 
not in the hepatocytes (Fig. 3). 
3.3. Sequence results 
Direct sequencing of PCR products confirmed that the 
nucleotide sequence of amplified cDNA was identical to 
CGRP I mRNA [7] in the region delimited by the primers 
used (beginning of exon 5 to the middle of exon 6) (data 
not shown)). 
4. Discussion 
We recently reported [l] the presence of calcitonin 
mRNA and peptide in liver tissue and in primary cul- 
tures of hepatocytes. This implicates that active tran- 
scription of the CALC I gene is occuring in hepatic tissue 
in vivo and in vitro. As the CALC I gene also expresses 
by alternated splicing of a primary transcript CGRP, we 
used the PCR technique to establish if CGRP messengers 
are synthesized in hepatic tissue and in hepatocytes. The 
specificity of the PCR reaction was established by hy- 
bridization with a hCGRP specific probe and further 
confirmed by sequencing the amplified cDNA. The mes- 
senger expressed in the liver is polyadenylated as we used 
oligo(dT) and reverse transcriptase to obtain the first 
cDNA copy. 
Table 1 
Primers Sequence 5’-3’ 
Pit CAG CCT GTG ACA CTG CCA CC Exon 5 
CGRP I 
CGRP II 
P12 GCG GCG CCT GCC AAA GGC Exon 5 antisense 
CGRP I 
CGRP II 
P19 GGT GGC TGA CGG GGC CTA GA Exon 6 
antisense 
CGRP I 
P20 GGT GGA GCT GCA TGA TCA AC Exon 6 
antisense 
CGRP II 
P39 GGT AAC TGC AAT GAG CTT Exon 6 
antisense 
CGRP I 
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Pl 1 219 
Pl 1 p12 (126pb) ++ 
5’ J EXON 1 1 EXON 2 1 EXON 3 1 EXON 5 1 EXON 6 1 
Coding exon 
CGRP I mRNA 
for CGRP I 
P’J_ 
z” 
P’L &12 (126pb) 
5’ 1 EXON 1 1 EXON 2 1 EXON 3 1 EXON 5 1 WON 6 
Coding axon 
CGRP II mRNA 
for CGRP I I 
(398 pb) CGRP I specific 
3’ 
(421 pb) CGRP I I specific 
3’ 
Fig. 1. Schematic representation of CGRP I mRNA and CGRP II mRNA and position of primers used. The 2 messengers show important differences 
in nucleotide sequence in exon 6 (3’ non-coding exons) while exon 5 (CGRP coding exon) is highly conserved. 
Our results demonstrate that CGRP is synthesized in 
the liver as we detected the messenger and the peptide in 
extracts of that organ. Hepatic tissue expresses much 
higher levels of CGRP as compared to CT [l]. Thus in 
the liver either the alternative splicing events of the 
CALC I gene observed in nervous tissue predominates 
or the CGRP detected is produced by the CALC II gene. 
To examine these two possibilities we used specific prim- 
ers for CGRP II mRNA, and we detected much lower 
levels of CGRP II mRNA in liver as compared to CGRP 
I mRNA. This indicates that in quantitative terms 
CGRP I is the main form of CGRP expressed in the liver. 
Lower levels of CGRP messenger were detected in hepa- 
tocytes as compared to intact liver. This may in part be 
due to the presence of a corticoid in the culture medium 
as a reduction of CGRP mRNA in favor of CT mRNA 
has been reported when dexamethasone was added to TT 
cells in vitro [16]. The low levels of CGRP messenger 
could be also related to the dedifferentiation of hepato- 
cytes after 4 days in culture [17]. 
The CGRP peptide we detected in intact liver could 
thus be synthesized by the liver cells or originate from the 
nerves in the parenchyme of this organ or in the nerves 
fibers that form a dense plexus around the hepatic ves- 
sels. However, this organ is poorly innervated with 
CGRP containing fibers [18,19,20]. The liver contains 
several different types of cells including hepatocytes, Ito 
cells and Kuppfer cells. A probable source of the 
hormone in vivo could be the hepatocyte as we found 
both CGRP I messenger and peptide in primary cultures 
of these cells. We also detected the CGRP peptide in 
primary cultures of hepatocytes, using immunofluores- 
cent staining with a specific antibody against CGRP (un- 
published data). Endogenously produced CGRP could 
play a role in the regulation of glycogen metabolism in 
these cells as exogenous CGRP is able to counteract the 
effects of insulin on glycogen metabolism in isolated rat 
hepatocytes [21]. CGRP could also be implicated in cel- 
lular proliferation, as regeneration processes are active 
in the liver to repair the destructions provoked by chem- 
ical products such as drugs or alcohol as several recent 
reports indicate that CGRP may act as a local factor 
stimulating cellular proliferation. For example CGRP 
stimulates the proliferation of endothelial cells [22] and 
we have shown that CGRP is also involved in the prolif- 
eration of F9 teratocarcinoma cells [23]. 
Recent studies have indicated that CGRP receptors 
are only present in the non-parenchymal liver cells [24]. 
Our results suggest hat CGRP could be involved in a 
paracrine regulation of the non-parenchymal liver cells 
by the hepatocytes. CGRP secreted by these could thus 
play a role in the regulation of liver metabolism. Thus 
both peptides expressed by the CALC I gene appear to 
12345678 
12345678 
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Fig. 2. Left: agarose gel analysis of PCR products. Total RNAs ex- 
tracted from normal human liver, primary cultures of normal human 
hepatocytes (after 4 days of culture) and TT cells, were reverse-tran- 
scribed and amplified with specific exon 5 CGRP primers (~11, ~12). 
One-fourth of the reaction was electrophoresed. The 2% agarose gel 
contained 0.5 ,@ml ethidium bromide. Lanes I,5 = negative control 
without RNA; lanes 2,6 = primary cultures of normal human hepato- 
cytes; lanes 3,7 = normal human liver; lanes 4,8 = positive control (TT 
cells); lanes (5,6,7,8) = negative controls resulting from digestion of 
total RNA by RNase (1 mg/ml) for one hour at 37°C then reverse- 
transcribed and amplified with specific CGRP primers pl I and ~12. 
Right: autoradiogram of the Southern-blot hybridized, with [a-“PI- 
radiolabeled CGRP-specific probe. 
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Fig. 3. Autoradiogram of the Southern blot of PCR products hybrid- 
ized, with [a-32P]-radiolabeled CGRP-specific probe. Total RNAs ex- 
tracted from normal human liver, primary cultures of normal human 
hepatocytes (after 4 days of culture), were reverse-transcribed and am- 
plified with specific CGRP I or CGRP II primers. One-fourth of the 
reaction was electrophoresed. The 2% agarose gel contained 0.5 .&ml 
ethidium bromide. Lanes I ,4 = negative controls without RNA; lanes 
25 = primary cultures of normal human hepatocytes; lanes 3,6 = 
normal human liver; lanes l-3 = amplification with specific CGRP I 
primers (pl I and ~19); lanes 4-6 = amplification with specific CGRP 
II primers (pl I and ~20). 
be involved in an autocrine (CT) and a paracrine 
(CGRP) regulation of liver metabolism. Alternative 
splicing of the CALC I gene is thus not restricted to a 
tissue specific expression of these peptides but could also 
play a role in the regulation of a metabolic process by 
alternate expression of two different messengers. 
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